glp 1 magic GLP-1 and GIP: bullet for musculoskeletal diseases? We need to stop pretending

In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July

Psoriasis, a chronic inflammatory skin condition affecting 23% of the UK population, is closely linked to obesity and metabolic dysfunction

In fact, for most of us, making adjustments to increase GLP-1 naturallyeven if those changes are smallwill help us get to where we need to be

While GLP-1 therapies to date have conventionally been injectables, oral formulations are beginning to make their mark on the back of convenience and, therefore, better patient compliance

GLP-1RA corrects this imbalance through the following mechanisms: cell function protection and regeneration: GLP-1RA not only promotes insulin synthesis through cAMP-PKA pathway, but also realizes the increase of cell number and functional recovery by inhibiting cell apoptosis and promoting cell to cell transdifferentiation (for example, GCGR monoclonal antibody combined with GLP-1RA treatment can triple the number of cells in type 1 diabetes mice)